PT  - JOURNAL ARTICLE
AU  - Bhatt, Anant Narayan
AU  - Shenoy, Srinivas
AU  - Munjal, Sagar
AU  - Chinnadurai, Vijayakumar
AU  - Agarwal, Apurva
AU  - Kumar, A. Vinoth
AU  - Shanavas, A
AU  - Kanwar, Ratnesh
AU  - Chandna, Sudhir
TI  - 2-Deoxy-D-Glucose as an Adjunct to Standard of Care in the Medical Management of COVID-19: A Proof-of-Concept & Dose-Ranging Randomised Clinical Trial
AID  - 10.1101/2021.10.08.21258621
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.08.21258621
4099  - http://medrxiv.org/content/early/2021/10/10/2021.10.08.21258621.short
4100  - http://medrxiv.org/content/early/2021/10/10/2021.10.08.21258621.full
AB  - Objective To evaluate the efficacy and safety of 2-deoxy-D-glucose (2-DG) in the treatment of COVID-19.Participants 110 adults aged 18 to 65 years with moderate to severe COVID-19.Interventions 63, 90, and 126 mg/kg/day 2-DG plus standard of care (SOC) versus SOC only.Main Outcome Measures Times to maintaining SpO2 ≥94% on room air discharge, clinical recovery, vital signs normalisation, improvement by 1 and 2 points on WHO 10-point ordinal scale, negative conversion on RT-PCR, intensive care, and mortality.Results Patients treated with 90 mg/kg/day 2-DG plus SOC showed better outcomes. Time to maintaining SpO2 ≥94% was significantly shorter in the 2-DG 90 mg compared to SOC (median 2.5 days vs 5 days, Hazard ratio [95% confidence interval]=2.3 [1.14, 4.64], p=0.0201). Times to discharge from isolation ward, to clinical recovery, and to vital signs normalisation were significantly shorter for the 2-DG 90 mg group.All three doses of 2-DG were well tolerated. Thirty-three (30.3%) patients reported 65 adverse events and were mostly (86%) mild.Conclusion 2-DG 90 mg/kg/day as adjunct to SOC showed clinical benefits over SOC alone in the treatment of moderate to severe COVID-19. The promising trends observed in current phase-II study encourage confirmatory evaluation of the efficacy and safety of 2-DG in a larger phase-III trial.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2020/06/025664Clinical Protocols http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=44369&EncHid=&userName=2-deoxy-D-glucose Funding StatementINMAS-DRDO Delhi and Dr Reddy's Laboratory HyderabadAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Aakash Healthcare Institutional Ethics Committee Approved Anand Institutional Ethics Committee Approved Ethics Committee GSVM Medical College Approved IEC King George hospital Approved IEC, Jaslok Hospital and Research Centre Approved Institutional Ethics Committee, Govt. Medical College, Aurangabad Approved Institutional Ethics Committee, BGS Global Institute of Medical Sciences Approved Institutional Ethics Committee, Govt. Medical College, Nagpur Approved Institutional Ethics Committee-Chengalpattu Medical College Approved Institutional Ethics Committee-Clinical Studies, Indraprastha Apollo Hospital, New Delhi Approved King Georges Medical University Institutional Ethics Committee Approved Poona Medical Research Foundation Institutional Ethics Committee ApprovedI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGood amount of the data produced in the present work are contained in the manuscript. However, the data which could not be accommodated in the manuscript can be made available upon reasonable request to the authors